New treatment approaches for the management of Alzheimer's disease




Alzheimer’s disease, Cholinesterase, Memantine, Neurological disorders, Gene therapy


This assessment is mainly concerned with the new treatment approaches for the management of Alzheimer’s disease and how these procedures can be beneficial for patients suffering from such diseases. With various other brain diseases, the number of Alzheimer’s disease cases is also increasing day by day in the world. So, it has become very important to be aware of the various new methods for the treatment of Alzheimer’s disease. The new treatment methods that are been used for the treatment of such brain disorders are found to be highly beneficial, as various new therapies and methods are being discovered for the treatment of such brain diseases. The various medications that are being used for the treatment of such diseases are beneficial only when taken under proper guidance and amount. Various precautions are very necessary during the treatment of such diseases, which can be helpful in the treatment. These treatment procedures may vary from person to person depending on their age factor and health.


Download data is not yet available.


Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer’s disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA, 325(17), 1717-1718 (2021)

Ojajarvi J, Makela P, Rantasalo I. Failure of hand disinfection with frequent hand washing: a need for prolonged field studies. Journal of Hygiene (London), 79, 107–119 (1977)

Thimbleby H. Improving safety in medical devices and systems. Proceedings IEEE International Conference on Healthcare Informatics (2013) Available from:

Honigman B., Lee J., Rothschild J., Light P., Pulling R.M., Yu T., et al. Using computerized data to identify adverse drug events in outpatients. Journal of the American Medical Informatics Association, 8 (3), 254–66 (2001)

Lyons WE, et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA. 15239–15244 (1999)

Visscher RMS, Feddermann-Demont N, Romano F, Straumann D, Bertolini G. Artificial intelligence for understanding concussion: Retrospective cluster analysis on the balance and vestibular diagnostic data of concussion patients. PLoS ON, 14(4), e0214525 (2019)

Mendoza-Salonga A, Nutrition and brain development. S Afr Fam Pract 49(3), 40–42 (2007)

Alzheimer’s disease Facts and figures. Rep. Vol 6. Chicago: Al-zheimer’s Association (2010)

Beal MF. Oxidatively modified proteins in aging and disease1, 2. Free Radical Biology and Medicine, 32(9), 797-803 (2002)

Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. Journal of Neuroinflammation, 2(1), 23 (2005)

Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid β peptide. Biochimica et Biophysica Acta (BBA)—Biomembranes. 1768(8), 1976-1990 (2007)

Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun.120(3), 885–90 (1984)

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev (1), CD005593 (2006)

Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs, 66 ( 11 ), 1515 – 34 (2006)

Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers. Res. Ther., 6, 37 (2014)

Fish PV, Steadman D, Bayle ED, Whiting P. New approaches for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 29, 125-33 (2019)

Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Yaffe K, Kramer JH, Reed B, Norman D et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 71, 441–447 (2001)

Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, et al. Nerve growth factor gene therapy activation of neuronal responses in Alzheimer Disease. JAMA Neurol, 72(10), 1139-1147 (2015)

Peisah C, Lawrence G, Reutens S. Creative solutions for severe dementia with BPSD: A case of art therapy used in an inpatient and residential care setting. Int Psychogeriatr., 23(6), 1011 – 3 (2011)

Wheeler B. The Relationship between Music Therapy and Theories of Psy-chotherapy. Music Therapy. The Journal of the American Association for Music Therapy, 1, 9-16 (1981)

Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 52, 1-18 (2015)

Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacology & Therapeutics. 134(1), 8-25 (2012)

Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends in Molecular Medicine. 21(6), 394-402 (2015)

Jedrziewski MK, Ewbank DC, Wang H, Trojanowski JQ. The impact of exercise, cognitive activities, and socialization on cognitive function: results from the national long-term care survey. American Journal of Alzheimer’s Disease & Other Dementias, 29(4), 372–378 (2014)

Van de Rest O, Berendsen AAM, Haveman-Nies A, de Groot L CPGM: Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr., 6, 154-68 (2015)

Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol, 14, 653–666 (2018)



How to Cite

Abhishek, & Pahwa, S. (2022). New treatment approaches for the management of Alzheimer’s disease. Journal of Applied Pharmaceutical Research, 10(2), 01-08.